PHARVARIS NV(NASDAQ:PHVS) stock News

PHVS Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Pharvaris N.V.

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Pharvaris N.V.

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

4 months ago - By: Pharvaris N.V.

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

8 months ago - By: Pharvaris N.V.

Pharvaris Outlines 2025 Strategic Priorities

2 months ago - By: Pharvaris N.V.

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2 months ago - By: Pharvaris N.V.

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

2 months ago - By: Pharvaris N.V.

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

2 months ago - By: Pharvaris N.V.

Pharvaris Announces Proposed Public Offering of Ordinary Shares

2 months ago - By: Pharvaris N.V.

Pharvaris Announces Proposed Public Offering of Ordinary Shares

2 months ago - By: Pharvaris N.V.

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

2 months ago - By: Pharvaris N.V.

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

2 months ago - By: Pharvaris N.V.

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

2 months ago - By: Pharvaris N.V.

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

3 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

3 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

3 months ago - By: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

3 months ago - By: Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

3 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

3 months ago - By: Pharvaris N.V.

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

4 months ago - By: Pharvaris N.V.

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

4 months ago - By: Pharvaris N.V.

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

4 months ago - By: Pharvaris N.V.

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Pharvaris N.V.

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

4 months ago - By: Pharvaris N.V.

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

5 months ago - By: Pharvaris N.V.

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: Pharvaris N.V.

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: Pharvaris N.V.

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

5 months ago - By: Pharvaris N.V.

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

6 months ago - By: Pharvaris N.V.

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

6 months ago - By: Pharvaris N.V.

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

6 months ago - By: Pharvaris N.V.

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

6 months ago - By: Pharvaris N.V.

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

8 months ago - By: Pharvaris N.V.

Pharvaris Outlines 2025 Strategic Priorities

10 months ago - By: Pharvaris N.V.

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

10 months ago - By: Pharvaris N.V.

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

10 months ago - By: Pharvaris N.V.

PHARVARIS NV (PHVS) Stock News

PHVS Latest News, Press Relases and Analysis

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Pharvaris Outlines 2025 Strategic Priorities

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Pharvaris Announces Proposed Public Offering of Ordinary Shares

Pharvaris Announces Proposed Public Offering of Ordinary Shares

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Pharvaris Announces Annual Meeting of Shareholders

Pharvaris Announces Annual Meeting of Shareholders

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Pharvaris Outlines 2025 Strategic Priorities

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference